Table 2.
Clinicopathological characteristics of metastatic disease a.
| Characteristics | Study Groups | P-Value | ||
|---|---|---|---|---|
| CE-CT | PET/CT | |||
| Year of diagnosis | 2015 (2010–2017) | 2016 (2009–2017) | 0.02 | |
| Age at diagnosis (year) | 67.0 (31.0–84.5) | 63.4 (32.9–85.8) | 0.69 | |
| Performance status | 0 | 12 (35.3) | 13 (41.9) | 0.36 |
| 1 | 10 (29.4) | 13 (41.9) | ||
| ≥2 | 3 (8.8) | 1 (3.2) | ||
| Unknown | 9 (26.5) | 4 (12.9) | ||
| Time until relapse b (months) | 78.0 (0–271.4) | 81.8 (0–307.5) | 0.71 | |
| Histopathology | Ductal | 4 (11.8) | 5 (16.1) | 0.86 |
| Lobular | 4 (11.8) | 2 (6.5) | ||
| Adenocarcinoma | 18 (52.9) | 18 (58.1) | ||
| Unknown | 8 (23.5) | 6 (19.4) | ||
| De novo metastatic cancer | 8 (25.5) | 4 (12.9) | 0.35 | |
| Estrogen receptor status | Positive | 30 (88.2) | 28 (90.3) | 0.50 |
| Negative | 2 (5.9) | 3 (9.7) | ||
| Unknown | 2 (5.9) | 0 (0) | ||
| HER-2 status | Positive | 5 (14.7) | 6 (19.4) | 0.46 |
| Negative | 22 (64.7) | 22 (71.0) | ||
| Unknown | 7 (20.6) | 3 (9.7) | ||
| Origin of biopsy | Bone | 5 (14.7) | 13 (41.9) | 0.07 |
| Liver | 6 (17.7) | 3 (9.7) | ||
| Lung/Pleural fluid | 8 (23.5) | 7 (22.6) | ||
| Breast/lymph nodes | 15 (44.1) | 8 (25.7) | ||
| Region of metastases at baseline scan | Bone-only metastasis | 4 (11.8) | 4 (12.9) | 0.89 |
| Bone | 22 (64.7) | 21 (67.7) | 0.80 | |
| Liver | 8 (25.5) | 8 (25.8) | 0.83 | |
| Lung | 10 (29.4) | 11 (35.5) | 0.60 | |
| Regional lymph nodes | 12 (35.3) | 9 (29.0) | 0.59 | |
| Distant lymph nodes | 18 (52.9) | 17 (54.8) | 0.88 | |
| Pleura/pleural effusion | 3 (8.8) | 6 (19.4) | 0.22 | |
| Breast/local recurrence | 7 (20.6) | 6 (19.4) | 0.90 | |
| Soft tissue | 1 (2.9) | 4 (12.9) | 0.13 | |
| Others c | 2 (5.9) | 3 (9.7) | 0.57 | |
CE-CT: contrast-enhanced computed tomography; FDG-PET/CT: fluorodeoxyglucose positron emission tomography with integrated computed-tomography, HER-2: human epidermal growth factor receptor-2. a Data shown as median (interquartile range) and frequency (%). b Time until relapse for patients with primary disseminated disease was considered zero. c Others comprised ascites, adrenal glands, thyroid, uterus, colon, and skin.